Past event

This event has already taken place

Want to be part of a future PharmaBrands event? Get in touch and we’ll help you find the right one.

Pav Rishiraj

Director, Head of Pharmacovigilance & UK QPPV · IPSEN & ABPI Chair of Pharma Convigilance

Become a speaker
IPSEN & ABPI Chair of Pharma Convigilance

Pav Rishiraj

Director, Head of Pharmacovigilance & UK QPPV

IPSEN & ABPI Chair of Pharma Convigilance

A visionary and senior Pharmacovigilance (PV)/Patient Safety leader with extensive detailed experience spanning 21 years across multiple functions including global/local positions, Pav Rishiraj has held senior management/leadership positions, to ensure strict compliance to UK, European and global regulatory obligations. His experience has enabled facilitation of strong cross-functional collaboration and transformational change across all the organisations he has served., through inclusive, empowering leadership, Pav’s passionate advocacy and empowering approach to patient safety remains apparent in full abundance. Pav is currently a Director of PV at Ipsen Biopharma and continues to Chair the ABPI Pharmacovigilance Expert Network (PEN) for over 5 years. He remains ever committed to ensuring and propelling forward innovative approaches to patient safety and is currently a member of the International Society of Pharmacovigilance (ISoP). This strategic experience has enabled him to influence, shape and advocate the PV landscape from an industry perspective with stakeholders such as the MHRA, EMA, NHS, and the BHBIA. Pav also serves as a member of the Board Steering Group (BSG) at the ABPI to represent UK PV and drive forward Regulatory Science objectives at the policy level - largely to evolve a robust and respected regulatory framework with clear strategy for collaboration within the UK and internationally.

Pav Rishiraj

Sessions

  1. Pav Rishiraj

    Pav Rishiraj

    10:50 AM – 11:30 AM

    A Real Debate on What’s Coming Next: Ethics, Regulation & the EU AI Act

    • The EU’s AI Act will reshape how pharma markets, personalises, and measures. This panel explore pharma frameworks, and how to stay compliant without holding back innovation.

    Outcome: Leave a strong understanding of how AI solutions may violate the EU AI Act. Critical for those tasked with rolling out global initiatives in EU markets.

    • Pav Rishiraj, Director, Head of Pharmacovigilance & UK QPPV, IPSEN & ABPI Chair of Pharma Convigilance

    • Jasmine Agyekum,, Senior Associate, Clifford Chance

    • Amman Ayub, Lead Counsel, UK & Ireland, Advanz Pharma